Current Report Filing (8-k)
May 08 2019 - 4:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
May 8, 2019
PROVENTION BIO, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-38552
|
|
81-5245912
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
P.O.
Box 666, Oldwick, New Jersey 08858
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(908) 336-0360
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Securities
registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchanged on Which Registered
|
Common Stock, $0.0001 par value per share
|
|
PRVB
|
|
The Nasdaq Capital Market
|
Item
2.02. Results of Operations and Financial Condition.
On
May 8, 2019, Provention Bio, Inc. (the “Company”) issued a press release regarding financial results for the fiscal
quarter ended March 31, 2019. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
The
information in this Current Report on Form 8-K under this Item 2.02, including the information contained in Exhibit 99.1, is being
furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities
of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as
amended or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) The following exhibit is furnished with
this report:
SIGNATURE
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly author
ized.
|
Provention Bio, Inc.
|
|
|
|
Date: May 8, 2019
|
By:
|
/s/ Andrew Drechsler
|
|
|
Andrew Drechsler
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Apr 2023 to Apr 2024